Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT05247905)
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu 177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors.
Who can join: Review the eligibility criteria below.
Location: Fairbanks Memorial Hospital — Fairbanks, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (171 Sites)
Showing the first 25 of 171 sites.
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Tower Cancer Research Foundation — Beverly Hills, California
- Epic Care-Dublin — Dublin, California
- Bay Area Breast Surgeons Inc — Emeryville, California
- Epic Care Partners in Cancer Care — Emeryville, California
- Cedars Sinai Medical Center — Los Angeles, California
- Contra Costa Regional Medical Center — Martinez, California
- Bay Area Tumor Institute — Oakland, California
- Torrance Memorial Physician Network - Cancer Care — Torrance, California
- Epic Care Cyberknife Center — Walnut Creek, California
- BASS Medical Group - Lennon — Walnut Creek, California
- Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
- Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
- The Women's Imaging Center — Denver, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
- Presbyterian - Saint Lukes Medical Center - Health One — Denver, Colorado
- Rocky Mountain Cancer Centers-Midtown — Denver, Colorado
- Rocky Mountain Cancer Centers-Rose — Denver, Colorado
- Mountain Blue Cancer Care Center - Swedish — Englewood, Colorado
- Rocky Mountain Cancer Centers - Swedish — Englewood, Colorado
- The Melanoma and Skin Cancer Institute — Englewood, Colorado
- Rocky Mountain Cancer Centers-Lakewood — Lakewood, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Pancreatic Neuroendocrine Tumor
Explore by condition: All Metastatic Pancreatic Neuroendocrine Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.